Latest Articles
Ep. 6 - The Invisible Illness Impacting Millions of Women - dailywire.com
Ep. 6 - The Invisible Illness Impacting Millions of Women dailywire.com
Published: April 18, 2026, 5:02 p.m.
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy TipRanks
Published: April 15, 2026, 1:38 p.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - The Manila Times
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression The Manila Times
Published: April 15, 2026, 11:45 a.m.
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - GlobeNewswire
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression GlobeNewswire
Published: April 15, 2026, 11:30 a.m.
New clinic helping woman with 'life-impacting conditions' opens in Wagga - The Daily Advertiser
New clinic helping woman with 'life-impacting conditions' opens in Wagga The Daily Advertiser
Published: March 31, 2026, 5:31 a.m.
International Women’s Day: Major study reveals biggest issues impacting Australian women and girls - The West Australian
International Women’s Day: Major study reveals biggest issues impacting Australian women and girls The West Australian
Published: March 7, 2026, 8 p.m.
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women - GlobeNewswire
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women GlobeNewswire
Published: Jan. 12, 2026, 12:30 p.m.
Child 'approached' by person 'acting suspiciously' near Basildon primary school - Essex Live
Child 'approached' by person 'acting suspiciously' near Basildon primary school Essex Live
Published: Dec. 19, 2025, 9:19 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
EVE Health Group Launches Fast-Acting Women’s And Men’s Health Products - Sharecafe
EVE Health Group Launches Fast-Acting Women’s And Men’s Health Products Sharecafe
Published: Sept. 26, 2025, 12:07 a.m.
Link copied to clipboard!